CR9980A - Imidazolinas 4,4,5,5 tetrasustituidas - Google Patents
Imidazolinas 4,4,5,5 tetrasustituidasInfo
- Publication number
- CR9980A CR9980A CR9980A CR9980A CR9980A CR 9980 A CR9980 A CR 9980A CR 9980 A CR9980 A CR 9980A CR 9980 A CR9980 A CR 9980A CR 9980 A CR9980 A CR 9980A
- Authority
- CR
- Costa Rica
- Prior art keywords
- tetrasustituidas
- imidazolins
- esters
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74122305P | 2005-12-01 | 2005-12-01 | |
US85274706P | 2006-10-19 | 2006-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9980A true CR9980A (es) | 2008-06-18 |
Family
ID=37866229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9980A CR9980A (es) | 2005-12-01 | 2008-05-16 | Imidazolinas 4,4,5,5 tetrasustituidas |
Country Status (18)
Country | Link |
---|---|
US (1) | US7851626B2 (ru) |
EP (3) | EP2130822A1 (ru) |
JP (1) | JP4870778B2 (ru) |
KR (2) | KR101109437B1 (ru) |
CN (1) | CN101316823B (ru) |
AR (1) | AR057990A1 (ru) |
AU (1) | AU2006319248B2 (ru) |
BR (1) | BRPI0619236A2 (ru) |
CA (1) | CA2630410C (ru) |
CR (1) | CR9980A (ru) |
ES (1) | ES2538714T3 (ru) |
HK (1) | HK1126216A1 (ru) |
MA (1) | MA31550B1 (ru) |
NO (1) | NO20082389L (ru) |
NZ (1) | NZ568285A (ru) |
RU (1) | RU2442779C2 (ru) |
TW (1) | TWI326681B (ru) |
WO (1) | WO2007063013A1 (ru) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2104665A2 (en) * | 2006-10-19 | 2009-09-30 | F. Hoffmann-Roche AG | Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes |
AU2007312390B2 (en) * | 2006-10-19 | 2013-03-28 | F. Hoffmann-La Roche Ag | Aminomethyl-4-imidazoles |
EP2192111A3 (en) * | 2007-07-06 | 2010-10-06 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing substituted tetracycline compounds |
EP2325180A1 (en) * | 2007-10-09 | 2011-05-25 | F. Hoffmann-La Roche AG | Chiral CIS-imidazolines |
WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
EP2298778A4 (en) | 2008-06-12 | 2011-10-05 | Daiichi Sankyo Co Ltd | IMIDAZOTHIAZOL DERIVATIVE WITH 4,7-DIAZASPIRO [2.5] OCTAN RING STRUCTURE |
KR20110119641A (ko) | 2009-01-16 | 2011-11-02 | 다이이찌 산쿄 가부시키가이샤 | 프롤린 고리 구조를 갖는 이미다조티아졸 유도체 |
EA201200321A1 (ru) * | 2009-08-26 | 2012-09-28 | Новартис Аг | Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4 |
MX2012004377A (es) | 2009-10-14 | 2012-06-01 | Merck Sharp & Dohme | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos. |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
EP2621275B1 (en) | 2010-09-30 | 2018-03-28 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
WO2012080389A1 (en) | 2010-12-16 | 2012-06-21 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor |
US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
AU2012316055B2 (en) | 2011-09-27 | 2016-05-12 | Amgen Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
JP2015502366A (ja) | 2011-12-13 | 2015-01-22 | バック インスティテュート フォー リサーチ オン エイジング | 薬物療法を改善するための方法 |
WO2013096150A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
TWI654180B (zh) | 2012-06-29 | 2019-03-21 | 美商艾佛艾姆希公司 | 殺真菌之雜環羧醯胺 |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
WO2014082889A1 (en) * | 2012-11-28 | 2014-06-05 | F. Hoffmann-La Roche Ag | Novel imidazolines as dual inhibitors of mdm2 and mdmx |
US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
AR094116A1 (es) | 2012-12-20 | 2015-07-08 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de hdm2 |
CN103012272B (zh) * | 2012-12-21 | 2015-01-28 | 江苏国泰超威新材料有限公司 | 一种咪唑啉化合物的制备方法 |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
JP6266659B2 (ja) | 2013-02-28 | 2018-01-24 | アムジエン・インコーポレーテツド | 癌の治療のための安息香酸誘導体mdm2阻害剤 |
AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
RU2016101514A (ru) * | 2013-07-03 | 2017-08-08 | Ф. Хоффманн-Ля Рош Аг | ЭКСПРЕССИЯ мРНК ГЕНОВ ДЛЯ ПЕРСОНАЛИЗАЦИИ ПРОТИВООПУХОЛЕВОЙ ТЕРАПИИ ПАЦИЕНТОВ АНТАГОНИСТОМ MDM2 |
US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
SG11201608667SA (en) | 2014-04-17 | 2016-11-29 | Univ Michigan | Mdm2 inhibitors and therapeutic methods using the same |
MX2018000360A (es) * | 2015-07-10 | 2018-06-11 | Arvinas Inc | Moduladores basados en mdm2 de proteolisis y metodos de uso asociados. |
PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
KR20200035944A (ko) | 2017-06-16 | 2020-04-06 | 유니티 바이오테크놀로지, 인크. | 약제학적 용도를 위해 에난티오머적으로 순수한 시스-이미다졸린 화합물을 제조하기 위한 합성 방법 |
WO2019195851A1 (en) * | 2018-04-06 | 2019-10-10 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
KR102039696B1 (ko) | 2018-04-23 | 2019-11-04 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법 |
KR102622992B1 (ko) | 2021-03-29 | 2024-01-10 | 주식회사 퓨전바이오텍 | 이미다졸린 유도체 및 이의 중간체 제조방법 |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02101065A (ja) | 1988-10-06 | 1990-04-12 | Tanabe Seiyaku Co Ltd | イミダゾリン誘導体及びその製法 |
EP0786455B1 (en) * | 1994-09-26 | 2003-12-03 | Shionogi & Co., Ltd. | Imidazole derivative |
GB2351082A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Synthesis of Cyclic Substituted Amidines |
DE60227108D1 (de) | 2001-12-18 | 2008-07-24 | Hoffmann La Roche | Cis-imidazoline als mdm2-hemmer |
DE60225719T2 (de) * | 2001-12-18 | 2009-04-23 | F. Hoffmann-La Roche Ag | Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren |
US6878735B2 (en) * | 2002-05-31 | 2005-04-12 | Board Of Trustees Of Michigan State University | Multi-substituted imidazolines and method of use thereof |
US7345078B2 (en) * | 2002-05-31 | 2008-03-18 | The Board Of Trustees Of Michigan State University | NF-κB inhibitors and uses thereof |
US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
JP2006527712A (ja) * | 2003-06-17 | 2006-12-07 | エフ.ホフマン−ラ ロシュ アーゲー | シス−2,4,5−トリアリール−イミダゾリン |
US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
CN100562316C (zh) * | 2003-06-17 | 2009-11-25 | 霍夫曼-拉罗奇有限公司 | 作为mdm2抑制剂的顺式咪唑啉 |
KR20080027969A (ko) | 2004-05-18 | 2008-03-28 | 에프. 호프만-라 로슈 아게 | 신규 cis-이미다졸린 |
US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
-
2006
- 2006-11-22 EP EP09166803A patent/EP2130822A1/en not_active Withdrawn
- 2006-11-22 BR BRPI0619236-0A patent/BRPI0619236A2/pt not_active Application Discontinuation
- 2006-11-22 WO PCT/EP2006/068748 patent/WO2007063013A1/en active Application Filing
- 2006-11-22 AU AU2006319248A patent/AU2006319248B2/en not_active Ceased
- 2006-11-22 CN CN2006800448100A patent/CN101316823B/zh not_active Expired - Fee Related
- 2006-11-22 EP EP20060819663 patent/EP1960368B1/en active Active
- 2006-11-22 EP EP10175570A patent/EP2311814A1/en not_active Withdrawn
- 2006-11-22 ES ES06819663.3T patent/ES2538714T3/es active Active
- 2006-11-22 KR KR1020087013226A patent/KR101109437B1/ko active IP Right Grant
- 2006-11-22 NZ NZ568285A patent/NZ568285A/en not_active IP Right Cessation
- 2006-11-22 CA CA2630410A patent/CA2630410C/en not_active Expired - Fee Related
- 2006-11-22 KR KR1020107024025A patent/KR20100129331A/ko not_active Application Discontinuation
- 2006-11-22 JP JP2008542723A patent/JP4870778B2/ja not_active Expired - Fee Related
- 2006-11-22 RU RU2008126383/04A patent/RU2442779C2/ru active
- 2006-11-27 US US11/604,558 patent/US7851626B2/en not_active Expired - Fee Related
- 2006-11-29 TW TW095144209A patent/TWI326681B/zh not_active IP Right Cessation
- 2006-11-29 AR ARP060105272A patent/AR057990A1/es not_active Application Discontinuation
-
2008
- 2008-05-16 CR CR9980A patent/CR9980A/es not_active Application Discontinuation
- 2008-05-26 NO NO20082389A patent/NO20082389L/no not_active Application Discontinuation
- 2008-06-02 MA MA30992A patent/MA31550B1/fr unknown
-
2009
- 2009-06-01 HK HK09104901.1A patent/HK1126216A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20100129331A (ko) | 2010-12-08 |
TW200804297A (en) | 2008-01-16 |
JP2009517439A (ja) | 2009-04-30 |
CA2630410C (en) | 2014-02-25 |
EP1960368B1 (en) | 2015-05-06 |
KR101109437B1 (ko) | 2012-01-31 |
CN101316823A (zh) | 2008-12-03 |
EP2311814A1 (en) | 2011-04-20 |
AR057990A1 (es) | 2008-01-09 |
NZ568285A (en) | 2011-08-26 |
AU2006319248B2 (en) | 2012-09-27 |
HK1126216A1 (en) | 2009-08-28 |
ES2538714T3 (es) | 2015-06-23 |
BRPI0619236A2 (pt) | 2011-09-20 |
CN101316823B (zh) | 2013-05-22 |
US20070129416A1 (en) | 2007-06-07 |
MA31550B1 (fr) | 2010-08-02 |
EP2130822A1 (en) | 2009-12-09 |
TWI326681B (en) | 2010-07-01 |
EP1960368A1 (en) | 2008-08-27 |
RU2442779C2 (ru) | 2012-02-20 |
AU2006319248A1 (en) | 2007-06-07 |
WO2007063013A1 (en) | 2007-06-07 |
CA2630410A1 (en) | 2007-06-07 |
US7851626B2 (en) | 2010-12-14 |
KR20080072894A (ko) | 2008-08-07 |
RU2008126383A (ru) | 2010-01-10 |
NO20082389L (no) | 2008-08-18 |
JP4870778B2 (ja) | 2012-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9980A (es) | Imidazolinas 4,4,5,5 tetrasustituidas | |
DK2235017T3 (da) | Spiroindolinonderivater som anticancermidler | |
ATE519764T1 (de) | Spiroindolinon-derivate | |
EA200801144A1 (ru) | Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич | |
CR8744A (es) | Compuestos terapeuticos | |
MY160424A (en) | Substituted pyrrolidine-2-carboxyamides. | |
CR11518A (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
HRP20120323T1 (en) | Diarylhydantoin compounds | |
CR10148A (es) | Derivados de las benzamidas y heteroarenos | |
UY33226A (es) | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 | |
BRPI0717266A2 (pt) | Derivados de oxindol | |
UY29963A1 (es) | Compuestos terapéuticos: piridinas y pirazinas como andamios | |
CU23413B7 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos | |
UY31546A1 (es) | Derivados bis-(sulfonilamino) en terapia 205 | |
UY29826A1 (es) | Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones | |
ATE495176T1 (de) | Spiroindolinon-derivate | |
TW200745032A (en) | Novel heterobicyclic derivatives | |
ECSP088677A (es) | Piperazinas y piperidinas como potenciadores 157 del mglur5 | |
ATE528290T1 (de) | Spiroindolinon-derivate | |
UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
CO6420347A2 (es) | Derivados de imidazotiazol que tienen estructura de anillo de prolina | |
UY27980A1 (es) | Indoles 2,7-sustituidos | |
AR057885A1 (es) | Acido 1-(1-(2- etoxietil) - 1- etil-7-(4- metilpiridin -2- ilamino)- 1h pirazolo (4,3-d) pirimidin -5- il) piperidina -4- carboxilico y las sales del mismo. composiciones farmaceuticas. | |
UY27959A1 (es) | Nuevos agonistas ppar alfa y ppar gama | |
UY29804A1 (es) | Quinolinas de alquilnitrilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |